Table 2.
Characteristics of the A-NB94 study cohort.
| Total | Non-MNA | MNA | hetMNA | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | <12 | ≥12 | Total | % | <12 | ≥12 | Total | <12 | ≥12 | Total | <12 | ≥12 | Total | |
| INSS Stage | GNB | 2 | 22 | 24 | 15% | 2 | 22 | 24 | ||||||
| 1 | 16 | 30 | 46 | 28% | 14 | 29 | 43 | 1 | 1 | 2 | 1 | 1 | ||
| 2 | 9 | 7 | 16 | 10% | 8 | 7 | 15 | 1 | 1 | |||||
| 3 | 14 | 9 | 23 | 14% | 12 | 5 | 17 | 1 | 4 | 5 | 1 | 1 | ||
| 4 | 12 | 32 | 44 | 27% | 6 | 18 | 24 | 5 | 14 | 19 | 1 | 1 | ||
| 4S | 10 | 10 | 6% | 10 | 10 | |||||||||
| Total | 63 | 100 | 163 | 100% | 52 | 81 | 133 | 7 | 19 | 26 | 4 | 4 | ||
| % | 39% | 61% | 100% | 32% | 50% | 82% | 4% | 12% | 16% | 2% | 2% | |||
Characteristics of the A-NB94 study cohort including risk-stratifying factors of disease stage according to the International Neuroblastoma Staging System (INSS), age (≤ or >12 months), and MYCN oncogene amplification (MNA) status including heterogeneous MNA (hetMNA). To appreciate differences in histopathology, we separated ganglioneuroblastoma (GNB) from other localized disease.